Comparison of Subjective Effects of Extended-Release Versus Immediate-Release Oxycodone/Acetaminophen Tablets in Healthy Nondependent Recreational Users of Prescription Opioids: A Randomized Trial

References

• . Brown AK, Christo PJ, Wu CL. Strategies for postoperative pain management. Best Pract Res Clin Anaesthesiol. 2004;18(4):703–717
   PubMedGoogle Scholar
• . Ripamonti CI, Bandieri E, Roila F, ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22( Suppl 6):vi69–77
   PubMed Web of Science ®Google Scholar
• . World Health Organization. WHO's pain relief ladder. http://www.who.int/cancer/palliative/painladder/en/. Accessed March 18, 2014
   Google Scholar
• . Airaksinen O, Brox JI, Cedraschi C, . European guidelines for the management of chronic nonspecific low back pain. Eur Spine J. 2006;15( Suppl 2):S192–S300
   PubMed Web of Science ®Google Scholar
• . American Society of Anesthesiologists Task Force on Chronic Pain Management, American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology. 2010;112(4):810–833
   PubMed Web of Science ®Google Scholar
• . Chou R, Fanciullo GJ, Fine PG, . Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–130
   PubMed Web of Science ®Google Scholar
• . Kahan M, Mailis-Gagnon A, Wilson L, Srivastava A. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 1: general population. Can Fam Physician. 2011;57(11):1257–1266, e1407–e1418
   PubMed Web of Science ®Google Scholar
• . Zhang W, Moskowitz RW, Nuki G, . OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137–162
   PubMed Web of Science ®Google Scholar
• . World Health Organization. Ensuring balance in national policies on controlled substances: Guidance for availability and accessibility of controlled medicines. http://whqlibdoc.who.int/publications/2011/9789241564175_eng.pdf?ua=1. Accessed February 19, 2014
   Google Scholar
• . Victor TW, Alvarez N, Gould E. Opioid prescribing practices in chronic pain management: guidelines do not sufficiently influence clinical practice. J Pain. 2009;10(10):1051–1057
   PubMed Web of Science ®Google Scholar
• . Gaskell H, Derry S, Moore RA, McQuay HJ. Single dose oral oxycodone and oxycodone plus paracetamol (acetaminophen) for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009;(3):CD002763
   Google Scholar
• . Butler SF, Black RA, Cassidy TA, Dailey TM, Budman SH. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J. 2011;8(1):29
   PubMed Web of Science ®Google Scholar
• . Comer SD, Ashworth JB, Sullivan MA, Vosburg SK, Saccone PA, Foltin RW. Relationship between rate of infusion and reinforcing strength of oxycodone in humans. J Opioid Manag. 2009;5(4):203–212
   PubMedGoogle Scholar
• . Marsch LA, Bickel WK, Badger GJ, . Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther. 2001;299(3):1056–1065
   PubMed Web of Science ®Google Scholar
• . de Wit H, Bodker B, Ambre J. Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacology (Berl). 1992;107(2–3):352–358
   PubMed Web of Science ®Google Scholar
• . Schoedel KA, McMorn S, Chakraborty B, Potts SL, Zerbe K, Sellers EM. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. J Opioid Manag. 2011;7(3):179–192
   PubMedGoogle Scholar
• . Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Investig Drugs. 2009;18(3):255–263
   PubMed Web of Science ®Google Scholar
• . Carise D, Dugosh KL, McLellan AT, Camilleri A, Woody GE, Lynch KG. Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry. 2007;164(11):1750–1756
   PubMed Web of Science ®Google Scholar
• . Katz N, Fernandez K, Chang A, Benoit C, Butler SF. Internet-based survey of nonmedical prescription opioid use in the United States. Clin J Pain. 2008;24(6):528–535
   PubMed Web of Science ®Google Scholar
• . Webster LR, Bath B, Medve RA, Marmon T, Stoddard GJ. Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone. Pain Med. 2012;13(6):790–801
   PubMed Web of Science ®Google Scholar
• . Setnik B, Roland CL, Cleveland JM, Webster L. The abuse potential of Remoxy®, an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med. 2011;12(4):618–631
   PubMed Web of Science ®Google Scholar
• . Singla N, Barrett T, Sisk L, Kostenbader K, Young J, Giuliani M. A randomized, double-blind, placebo-controlled study of the efficacy and safety of MNK-795, a dual-layer, biphasic, immediate-release and extended-release combination analgesic for acute pain. Curr Med Res Opin. 2014;30(3):349–359
   PubMed Web of Science ®Google Scholar
• . SAS Institute Inc. SAS OnlineDoc® 9.1. http://support.sas.com/91doc/docMainpage.jsp. Accessed April 17, 2014
   Google Scholar
• . US Food and Drug Administration. FDA recommends health care professionals discontinue prescribing and dispensing prescription combination drug products with more than 325 mg of acetaminophen to protect consumers [press release]. http://www.fda.gov/drugs/drugsafety/ucm381644.htm. Accessed February 20, 2014
   Google Scholar
• . Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 1971;12(2):245–258
   PubMed Web of Science ®Google Scholar
• . Romach MK, Schoedel KA, Sellers EM. Update on tamper-resistant drug formulations. Drug Alcohol Depend. 2013;130(1–3):13–23
   PubMed Web of Science ®Google Scholar
• . Stanos SP, Bruckenthal P, Barkin RL. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. Mayo Clin Proc. 2012;87(7):683–694
   PubMed Web of Science ®Google Scholar
• . Shram MJ, Sathyan G, Khanna S, . Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol. 2010;30(1):25–33
   PubMed Web of Science ®Google Scholar
• . Butler SF, Cassidy TA, Chilcoat H, . Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14(4):351–358
   PubMed Web of Science ®Google Scholar
• . Jang DH, Rohe JC, Hoffman RS, Nelson LS. Severe opioid withdrawal due to misuse of new combined morphine and naltrexone product (Embeda). Ann Emerg Med. 2010;55(3):303–304
   PubMed Web of Science ®Google Scholar
• . Ruan X, Chen T, Gudin J, Couch JP, Chiravuri S. Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature. J Opioid Manag. 2010;6(4):300–303
   PubMedGoogle Scholar
• . Bartholomäus J, Arkenau-Maric E, Galia E. Opioid extended-release tablets with improved tamper-resistant properties. Expert Opin Drug Deliv. 2012;9(8):879–891
   PubMed Web of Science ®Google Scholar
• . Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Benedek IH, Comer SD. Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend. 2012;126(1–2):206–215
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. FDA Statement: Original Opana ER Relisting Determination. http://www.fda.gov/Drugs/DrugSafety/ucm351357.htm. Accessed August 20, 2013
   Google Scholar
• . Watkins PB, Kaplowitz N, Slattery JT, . Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006;296(1):87–93
   PubMed Web of Science ®Google Scholar
• . Butler SF, Fernandez KC, Chang A, . Measuring attractiveness for abuse of prescription opioids. Pain Med. 2010;11:67–80
   PubMed Web of Science ®Google Scholar
• . Schoedel KA, McMorn S, Chakraborty B, Zerbe K, Sellers EM. Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. Pain Physician. 2010;13(6):561–573
   PubMed Web of Science ®Google Scholar
• . Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995; Ser. B 57(1):289–300
   Google Scholar